| |
Article Title |
Author(s) |
Type (Status) |
Available Online |
|
Atherosclerotic calcification relates to cognitive function and to brain changes on magnetic resonance imaging
DOI: 10.1016/j.jalz.2012.01.008
Abstract: Background: Increasing evidence suggests a role of atherosclerosis in the pathogenesis of cognitive impairment and dementia. Calcification volume measured with computed tomography (CT) is a ...
|
Daniel Bos,
Meike W. Vernooij,
Suzette E. Elias-Smale,
Benjamin F.J. Verhaaren,
Henri A. Vrooman,
Albert Hofman,
Wiro J. Niessen,
Jacqueline C.M. Witteman,
Aad van der Lugt,
M. Arfan Ikram
et al.
|
Full-length article
(In Press Corrected Proof)
|
26 April 2012 |
|
Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus
DOI: 10.1016/j.jalz.2011.05.2414
Abstract: Background: Diabetes and hypertension are independent risk factors for dementia, and hypertension may increase this risk in patients with diabetes. It is unclear whether antihypertensive dru...
|
Michael L. Johnson,
Niraj Parikh,
Mark E. Kunik,
Paul E. Schulz,
Jeetvan G. Patel,
Hua Chen,
Rajender R. Aparasu,
Robert O. Morgan
et al.
|
Full-length article
(In Press Corrected Proof)
|
23 April 2012 |
|
Fire in the ashes: Can failed Alzheimer’s disease drugs succeed with second chances?
DOI: 10.1016/j.jalz.2012.01.007
Abstract: Background: Since Cognex, more than 200 Alzheimer’s disease (AD) drug candidates have failed. Investigations have identified vulnerabilities of these AD drug developments to methodological e...
|
Robert E. Becker,
Nigel H. Greig
|
Full-length article
(In Press Corrected Proof)
|
05 April 2012 |
|
Gaining precision on the Alzheimer’s Disease Assessment Scale-cognitive: A comparison of item response theory-based scores and total scores
DOI: 10.1016/j.jalz.2011.05.2409
Abstract: Background: The Alzheimer’s Disease Assessment Scale-cognitive (ADAS-cog) is a commonly used measure for assessing cognitive dysfunction in patients with Alzheimer’s disease (AD). The measur...
|
Steve Balsis,
Alexis A. Unger,
Jared F. Benge,
Lisa Geraci,
Rachelle S. Doody
et al.
|
Full-length article
(In Press Corrected Proof)
|
05 April 2012 |
|
Butyrylcholinesterase genotype and gender influence Alzheimer’s disease phenotype
DOI: 10.1016/j.jalz.2010.12.005
Abstract: Retrospective data are presented to support a spectrum of early Alzheimer’s disease (AD) along a continuum defined by gender and genotype. The putative neurodegenerative mechanisms driving d...
|
Roger M. Lane,
Yunsheng He
|
Review article
(In Press Corrected Proof)
|
09 March 2012 |
|
Global gray matter changes in posterior cortical atrophy: A serial imaging study
DOI: 10.1016/j.jalz.2011.09.225
Abstract: Background: Posterior cortical atrophy (PCA) is a neurodegenerative condition predominantly associated with Alzheimer’s disease (AD) pathology. Cross-sectional imaging studies have shown dif...
|
Manja Lehmann,
Josephine Barnes,
Gerard R. Ridgway,
Natalie S. Ryan,
Elizabeth K. Warrington,
Sebastian J. Crutch,
Nick C. Fox
et al.
|
Full-length article
(In Press Corrected Proof)
|
27 February 2012 |
|
Amyloid imaging in dementias with atypical presentation
DOI: 10.1016/j.jalz.2011.07.003
Abstract: Background: With the potential emergence of disease specific therapies, an accurate biomarker of Alzheimer’s Disease pathology is needed in cases in which the underlying etiology is uncertai...
|
David A. Wolk,
Julie C. Price,
Charles Madeira,
Judy A. Saxton,
Beth E. Snitz,
Oscar L. Lopez,
Chester A. Mathis,
William E. Klunk,
Steven T. DeKosky
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 January 2012 |
|
Impact of the Food and Drug Administration’s antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settings
DOI: 10.1016/j.jalz.2011.08.004
Abstract: Background: Most patients with dementia also suffer from behavioral and psychological symptoms of dementia, for which there is no Food and Drug Administration-approved treatment. Objectives:...
|
Vibha C.A. Desai,
Pamela C. Heaton,
Christina M.L. Kelton
|
Short communication
(In Press Corrected Proof)
|
30 January 2012 |
|
Analysis of case management programs for patients with dementia: A systematic review
DOI: 10.1016/j.jalz.2011.06.004
Abstract: Background: People suffering from dementia are particularly vulnerable to the gaps between the health and social service systems. Case management is a professional field that seeks to fill i...
|
Dominique Somme,
Hélène Trouve,
Moustapha Dramé,
Dominique Gagnon,
Yves Couturier,
Olivier Saint-Jean
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 January 2012 |
|
Vascular risk factors, apolipoprotein E, and hippocampal decline on magnetic resonance imaging over a 10-year follow-up
DOI: 10.1016/j.jalz.2011.07.005
Abstract: Background: Decline of hippocampal volume on magnetic resonance imaging (MRI) may be considered as a surrogate biomarker of accumulating Alzheimer disease (AD) pathology. Previously, we show...
|
Tom den Heijer,
Fedde van der Lijn,
Arfan Ikram,
Peter J. Koudstaal,
Aad van der Lugt,
Gabriel P. Krestin,
Henri A. Vrooman,
Albert Hofman,
Wiro J. Niessen,
Monique M.B. Breteler
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 January 2012 |
|
Cardiovascular fitness is associated with altered cortical glucose metabolism during working memory in ɛ4 carriers
DOI: 10.1016/j.jalz.2011.04.010
Abstract: Background: The possibility that ɛ4 may modulate the effects of fitness in the brain remains controversial. The present exploratory FDG-PET study aimed to better understand the relationship ...
|
Sean P. Deeny,
Jeanna Winchester,
Kathryn Nichol,
Stephen M. Roth,
Joseph C. Wu,
Malcolm Dick,
Carl W. Cotman
et al.
|
Short communication
(In Press Corrected Proof)
|
09 January 2012 |
|
Association of environmental tobacco smoke with dementia and Alzheimer’s disease among never smokers
DOI: 10.1016/j.jalz.2011.09.231
Abstract: Background: Environmental tobacco smoke (ETS) is known to be harmful; however, its association with dementia remains controversial and with Alzheimer’s disease (AD) is unknown. Methods: Usin...
|
Ruoling Chen
|
Short communication
(In Press Corrected Proof)
|
26 December 2011 |
|
Some evolutionary perspectives on Alzheimer’s disease pathogenesis and pathology
DOI: 10.1016/j.jalz.2011.05.2408
Abstract: There is increasing urgency to develop effective prevention and treatment for Alzheimer’s disease (AD) as the aging population swells. Yet, our understanding remains limited for the elementa...
|
Daniel J. Glass,
Steven E. Arnold
|
Review article
(In Press Corrected Proof)
|
05 December 2011 |
|
Safety profile of Alzheimer’s disease populations in Alzheimer’s Disease Neuroimaging Initiative and other 18-month studies
DOI: 10.1016/j.jalz.2011.05.2413
Abstract: Background: Demonstration of a disease-modifying effect of a therapeutic agent on Alzheimer’s disease (AD) requires a trial lasting for at least 18 months. An understanding of expected rates...
|
David B. Henley,
Karen L. Sundell,
Gopalan Sethuraman,
Eric R. Siemers,
Alzheimer’s Disease Neuroimaging Initiative
et al.
|
Full-length article
(In Press Corrected Proof)
|
05 December 2011 |
|
Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid
DOI: 10.1016/j.jalz.2011.04.009
Abstract: Background: According to a widely accepted hypothesis, the amyloid precursor protein (APP) is processed by two competing pathways: the amyloidogenic β-secretase–mediated pathway or the nonam...
|
Panagiotis Alexopoulos,
Amalia Tsolakidou,
Francesco Roselli,
Anila Arnold,
Timo Grimmer,
Christine Westerteicher,
Maria Rosaria Leante,
Hans Förstl,
Paolo Livrea,
Alexander Kurz,
Robert Perneczky
et al.
|
Full-length article
(In Press Corrected Proof)
|
07 November 2011 |
|
Is Alzheimer’s disease amyloidosis the result of a repair mechanism gone astray?
DOI: 10.1016/j.jalz.2011.05.2429
Abstract: Here, we synthesize several lines of evidence supporting the hypothesis that at least one function of amyloid-β is to serve as a part of the acute response to brain hemodynamic disturbances ...
|
Tyler A. Kokjohn,
Chera L. Maarouf,
Alex E. Roher
|
Full-length article
(In Press Corrected Proof)
|
03 November 2011 |
|
Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels
DOI: 10.1016/j.jalz.2011.05.900
Abstract: Background: β-amyloid peptide (Aβ) is associated with neurodegeneration in Alzheimer’s disease. Emerging evidence indicates that Aβ levels in cerebrospinal fluid (CSF) may serve as an early ...
|
Jinhe Li,
Daniel A. Llano,
Teresa Ellis,
David LeBlond,
Anahita Bhathena,
Stanford S. Jhee,
Larry Ereshefsky,
Robert Lenz,
Jeffrey F. Waring
et al.
|
Full-length article
(In Press Corrected Proof)
|
03 November 2011 |
|
Effects of n-3 fatty acids on cognitive decline: A randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients
DOI: 10.1016/j.jalz.2011.06.002
Abstract: Background: Epidemiological studies suggest a protective effect of n-3 fatty acids derived from fish (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) against cognitive decline. F...
|
Johanna M. Geleijnse,
Erik J. Giltay,
Daan Kromhout
|
Full-length article
(In Press Corrected Proof)
|
04 October 2011 |